Log in

NASDAQ:PRPOPrecipio Stock Price, Forecast & News

$0.96
+0.12 (+14.57 %)
(As of 06/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.90
Now: $0.96
$1.06
50-Day Range
$0.59
MA: $0.72
$0.96
52-Week Range
$0.55
Now: $0.96
$5.53
Volume2.36 million shs
Average Volume1.31 million shs
Market Capitalization$10.69 million
P/E RatioN/A
Dividend YieldN/A
Beta2.62
Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, as well as PerkinElmer. The company is based in New Haven, Connecticut.
Read More
Precipio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRPO
CUSIPN/A
Phone203-787-7888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.13 million
Book Value$1.65 per share

Profitability

Net Income$-13,240,000.00
Net Margins-407.60%

Miscellaneous

Employees42
Market Cap$10.69 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable

Receive PRPO News and Ratings via Email

Sign-up to receive the latest news and ratings for PRPO and its competitors with MarketBeat's FREE daily newsletter.

Precipio (NASDAQ:PRPO) Frequently Asked Questions

How has Precipio's stock been impacted by COVID-19 (Coronavirus)?

Precipio's stock was trading at $1.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRPO stock has decreased by 17.9% and is now trading at $0.96. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Precipio?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precipio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Precipio.

When is Precipio's next earnings date?

Precipio is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Precipio.

How were Precipio's earnings last quarter?

Precipio (NASDAQ:PRPO) posted its earnings results on Thursday, August, 23rd. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $1.93 by $2.08. The biotechnology company earned $0.82 million during the quarter. Precipio had a negative return on equity of 109.58% and a negative net margin of 407.60%. View Precipio's earnings history.

When did Precipio's stock split? How did Precipio's stock split work?

Precipio shares reverse split before market open on Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for PRPO?

1 brokerages have issued twelve-month target prices for Precipio's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Precipio's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price. View analysts' price targets for Precipio.

Has Precipio been receiving favorable news coverage?

Media coverage about PRPO stock has trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Precipio earned a media sentiment score of -4.6 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutPrecipio.

Who are some of Precipio's key competitors?

What other stocks do shareholders of Precipio own?

Who are Precipio's key executives?

Precipio's management team includes the following people:
  • Mr. Ilan Danieli, Founder, Pres, CEO & Director (Age 47)
  • Mr. Carl R. Iberger, CFO & Sec. (Age 66)
  • Mr. Ahmed Zaki Sabet, Chief Operating Officer (Age 33)
  • Mr. Douglas Sites, VP of Sales
  • Mr. Ayman Mohamed, Sr. VP of R&D and Laboratory Operations (Age 34)

What is Precipio's stock symbol?

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

How do I buy shares of Precipio?

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Precipio's stock price today?

One share of PRPO stock can currently be purchased for approximately $0.96.

How big of a company is Precipio?

Precipio has a market capitalization of $10.69 million and generates $3.13 million in revenue each year. Precipio employs 42 workers across the globe.

What is Precipio's official website?

The official website for Precipio is www.precipiodx.com.

How can I contact Precipio?

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at 203-787-7888 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.